Repurposing the Antiparasitic Agent Praziquantel for Breast Neoplasm Therapy: A Narrative Review of the Mechanistic Rationale, Current Evidence and Translational Barriers

• Fatima Mohamed Osman

  Faculty of Medical Laboratory Sciences, University of Gadarif, Gadarif, Sudan

• Weam Alyoubi

  Department of Biological Science, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

• Tarteel Mohammed Ahmed

  Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan

• Jo'rayeva Gulhayo Jalol Qizi

  Department of Fundamental Medicine, Asia International University, Bukhara, Uzbekistan

• Nagat Bashir Siednamohammeddeen Ahmed

  Department of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia

• Nada Osman Yousif Elhaj

  Pediatric department ,College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia

• Tagwa Yousif Elsayed Yousif

  Department of Medical Laboratory Technology, College of Nursing and Health Sciences, Jazan University, Gizan, Saudi Arabia

• Marwan Ismail

  Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman, United Arab Emirates.

Background: Drug repurposing has become an established route into oncology because agents with a mature safety, pharmacokinetic and manufacturing record can be advanced faster and at lower cost than new chemical entities. Praziquantel, the mainstay of antischistosomal therapy for more than four decades, has been proposed as one such candidate.

Aim: This narrative review examines the case for repurposing praziquantel in breast neoplasia and does so critically rather than promotionally.

Results: Three strands of mechanistic rationale are identified: Praziquantel's target in the parasite is a TRPM channel, raising the untested hypothesis that it might also target the related human TRPM channels linked to breast tumour proliferation, migration and chemoresistance; the R-enantiomer is a partial agonist at the human 5-HT2B receptor, a node in a serotonergic pathway with documented roles in mammary tumour biology; and praziquantel has been proposed to lower the apoptotic threshold of carcinoma cells through down-regulation of the X-linked inhibitor of apoptosis protein which could improve the effects of cytotoxic chemotherapy. Against this rationale, the experimental evidence is limited. No study designed to evaluate praziquantel in a breast cancer model was identified. The syntheses that studied the praziquantel chemosensitising effect in combination with paclitaxel did not show direct antineoplastic activity as monotherapy; a single recent paper reported a monotherapy effect of praziquantel on hepatoma lines, but this has not been tested in breast cancer. A substantial exposure gap separates the concentrations at which activity is reported in vitro from those achievable clinically, given a systemic bioavailability below 20 per cent, a plasma half-life of one to three hours and approximately 80 per cent albumin binding. The favourable tolerability record derives from single-dose mass administration rather than chronic dosing alongside cytotoxic therapy.

Conclusion: We conclude that praziquantel is at present a hypothesis rather than a candidate in breast oncology, and we set out the specific studies that would be required to change that assessment.

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229-63.

[2] Saldias MP, Maureira D, Orellana-Serradell O, Silva I, Lavanderos B, Cruz P, et al. TRP channels interactome as a novel therapeutic target in breast cancer. Front Oncol 2021; 11: 621614.

[3] Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020; 5(1): 113.

[4] Pfab C, Schnobrich L, Eldnasoury S, Gessner A, El-Najjar N. Repurposing of antimicrobial agents for cancer therapy: what do we know? Cancers (Basel) 2021; 13(13): 3193.

[5] Laudisi F, Maronek M, Di Grazia A, Monteleone G, Stolfi C. Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system. Int J Mol Sci 2020; 21(14): 4957.

[6] Stolfi C, Pacifico T, Luiz-Ferreira A, Monteleone G, Laudisi F. Anthelmintic drugs as emerging immune modulators in cancer. Int J Mol Sci 2023; 24(7): 6446.

[7] Nogueira RA, Lira MGS, Lica ICL, et al. Praziquantel: an update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol 2022; 252: 111531.

[8] World Health Organization. WHO guideline on control and elimination of human schistosomiasis. Geneva: World Health Organization; 2022.

[9] Park SK, Friedrich L, Yahya NA, et al. Mechanism of praziquantel action at a parasitic flatworm ion channel. Sci Transl Med 2021; 13(625): eabj5832.

[10] Le Clec'h W, Chevalier FD, Mattos ACA, et al. Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel. Sci Transl Med 2021; 13(625): eabj9114.

[11] Yahya NA, Lanham JK, Sprague DJ, et al. Molecular and cellular basis of praziquantel action in the cardiovascular system. Am J Physiol Cell Physiol 2023; 324(2): C573-87.

[12] Kapungu NN, Li X, Nhachi C, Masimirembwa C, Thelingwani RS. In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel. Pharmacol Res Perspect 2020; 8(4): e00618.

[13] Zdesenko G, Mutapi F. Drug metabolism and pharmacokinetics of praziquantel: a review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis 2020; 14(9): e0008649.

[14] Gebreyesus TD, Makonnen E, Tadele T, Mekete K, Gashaw H, Gerba H, et al. Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: a prospective cohort study. Front Pharmacol 2023; 14: 968106.

[15] Ochoa SV, Casas Z, Albarracin SL, Sutachan JJ, Torres YP. Therapeutic potential of TRPM8 channels in cancer treatment. Front Pharmacol 2023; 14: 1098448.

[16] Cordier C, Prevarskaya N, Lehen'kyi V. TRPM7 ion channel: oncogenic roles and therapeutic potential in breast cancer. Cancers (Basel) 2021; 13(24): 6322.

[17] Balakrishna P, George S, Hatoum H, Mukherjee S. Serotonin pathway in cancer. Int J Mol Sci 2021; 22(3): 1268.

[18] Mao L, Xin F, Ren J, Xu S, Huang H, Zha X, et al. 5-HT2B-mediated serotonin activation in enterocytes suppresses colitis-associated cancer initiation and promotes cancer progression. Theranostics 2022; 12(8): 3928-45.

[19] Dai YJ, Sun JR, Hu TT, Liu XJ, Wang Y. Effects of praziquantel on the malignant biological behavior of hepatocellular carcinoma cells through 5-HT2B receptor. J Trop Dis Parasitol 2024; 22(3): 157-63.

[20] Mutiti CS, Kapungu NN, Kanji CR, Stadler N, Stingl J, Nhachi C, et al. Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir. Pharmacol Res Perspect 2021; 9(3): e00769.

[21] Madureira AC. Programmed cell death-ligand-1 expression in bladder schistosomal squamous cell carcinoma: there's room for immune checkpoint blockage? Front Immunol 2022; 13: 955000.

[22] Efared B, Bako ABA, Idrissa B, et al. Urinary bladder Schistosoma haematobium-related squamous cell carcinoma: a report of two fatal cases and literature review. Trop Dis Travel Med Vaccines 2022; 8: 3.

[23] Kasago FM, Haberli C, Keiser J, Masamba W. Design, synthesis and evaluation of praziquantel analogues and new molecular hybrids as potential antimalarial and anti-schistosomal agents. Molecules 2023; 28(13): 5184.

[24] Wu ZH, Lu MK, Hu LY, Li X. Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One 2012; 7(12): e51721.

[25] Chen L, Huang S, Wu X, He W, Song M. Serotonin signalling in cancer: emerging mechanisms and therapeutic opportunities. Clin Transl Med 2024; 14(7): e1750.

[26] Carmi I, Orosz A, Hajdó S, Zeöld A, Hegedűs T, Kelemen-Győri D, et al. The aggressive colorectal cancer subtype marker HTR2B has a dual role depending on the tumor microenvironment. Cell Commun Signal 2025; 23(1): 403.

[27] Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24(Suppl 2): S26-35.

• PDF

• Reviews

Copyright (c) 2026 Fatima Mohamed Osman, Weam Alyoubi, Tarteel Mohammed Ahmed, Jo'rayeva Gulhayo Jalol Qizi, Nagat Bashir Siednamohammeddeen Ahmed, Nada Osman Yousif Elhaj, Tagwa Yousif Elsayed Yousif, Marwan Ismail

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.